Management's prepared remarks and answers to your questions on today's call will contain forward-looking statements. As a ...

Why do some people feel chills when listening to music, reading poetry, or viewing a powerful work of art, while others do ...

Q4 2025 earnings call highlights: 2026 revenue outlook, Bako/StrataDx deals, AI pathology gains, and customer-loss risks—read now.

Myriad Genetics (NASDAQ:MYGN) executives highlighted fourth quarter and full-year 2025 results alongside a slate of planned ...

Myriad Genetics delivered a solid Q4 2025 earnings beat, with positive adjusted EPS and strong test volume growth. Click for ...

As of Friday, February 27, Fulgent Genetics, Inc.’s FLGT share price has dipped by 31.34%, which has investors questioning if this is right time to buy.

Sentinel participant showed OPGx-BEST1 was well tolerated with no ocular inflammation, treatment-related adverse events, or ...

Duckweed is the fastest-growing flowering plant, but new knowledge of duckweed genetics discovered by Adelaide University ...

The study offers one of the most detailed maps yet of how human antibody responses vary from person to person.

For more than a century, Mendelian genetics has shaped how we think about inheritance: one gene, one trait. It is a model that still echoes through textbooks—and one that is increasingly reaching its ...

Drivers of fourth quarter 2025 test volume growth year-over-year include Prolaris prostate cancer test at 12%, Hereditary ...

Shares of Fulgent Genetics tumbled after the company recorded a wider net loss in the fourth quarter and guided for lower-than-expected results in 2026. The stock plunged 32% to $16.84 in Friday ...